Pay in 4 interest-free payments of $5.08 Learn more
Ships within 48 hours · Estimated delivery Nov 5 - Nov 10
The fund has competitive expense ratios and maintains steady performance in non-U.S
Initial results of the Phase 3 ESSENCE trial looking at the effect of semaglutide on liver disease were released at the November 2024 American Association for the Study of Liver Diseases meeting
Pepping J (1999)
10.1073/pnas.88.23.10835 86 MukaiY.LupinacciR.MarderS.Snow-adamiL.VossT.SmithS
No serious adverse events, liver enzyme elevations, or cardiovascular changes were documented in the Phase 1 safety study published in the Journal of Clinical Endocrinology & Metabolism in 2024
US$ 28.26
US$ 25.89
US$ 26.95
